New Delhi’s pharmaceutical landscape is buzzing with optimism as India’s API market, worth $15-16 billion today, projects 5-7% CAGR through FY27 and FY28. CareEdge Ratings’ latest analysis points to favorable policies, evolving production strategies, and surging demand as key growth engines.
Companies are pivoting to complex, high-value APIs to navigate pricing pressures and secure better margins. This transition is bolstered by expanding footprints in both mature and developing markets, alongside growing local consumption.
Concerns persist over China’s dominance in essential raw material imports, yet government interventions are gaining traction. The PLI scheme and Bulk Drug Parks have fast-tracked over 30 projects, enabling new capacity rollouts by multiple players. ‘Progress is clear, though full benefits will unfold gradually,’ states the report.
Looking ahead, a promising lineup of potent APIs awaits commercialization, positioning India higher in the value chain. Expect tangible uplifts in 2-4 years once these initiatives hit production stride.
‘Demographic shifts like aging populations, better health infrastructure, insurance growth, chronic ailments, market liberalization, and global outreach will fuel sustained expansion,’ says Pritesh Rathi of CareEdge Ratings.
Bulk Drug Parks, spearheading 80% of current projects, promise transformative investments. Mega facilities in states like Andhra Pradesh, Himachal Pradesh, and Gujarat—each valued at 20-40 billion rupees—target self-reliance, import cuts, and operational efficiencies. This strategic push underscores India’s ambition to lead in API manufacturing worldwide.